Forget and Menzies (2006)
Canada
|
Systematic review (literature search of Medline, relevant articles from authors’ files and pearled references from cited articles)
Quality appraisal: poor
High risk of bias
|
Research question:
NS
Included studies:
NS
|
Active TB patients
Latent TB patients
TB patients on multidrug regimens
|
Isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin
Multidrug regimens
|
Various
|
Discontinuation rate
AE rate
Mortality rate
Risk factors for development of AEs
|
Frydenberg & Graham (2009)
Australia
|
Systematic review (literature search of PubMed, EMBASE and Cochrane Library Reference, hand-search of reference lists)
Quality appraisal: medium
Some risk of bias
|
Research question:
To review the frequency and manifestations of toxicities in children to current first-line anti-TB therapy
Included studies:
NS
|
Children (0–18 years of age) undergoing first-line therapy for TB, or therapy for latent TB
|
Anti-TB agents, isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin
Combination therapies
|
NS
|
Adverse reaction incidence
AE rate
|
van der Werf et al. (2012)
The Netherlands
|
Systematic review and meta-analysis (methodology according to the Cochrane Handbook for Systematic Reviews and PRISMA)
Quality appraisal: good
Low risk of bias
|
Research question:
To assess the risk of development of MDR-TB after the use of inappropriate TB regimens
Included studies:
4 (2 studies included in meta-analysis)
|
Non-MDR patients receiving treatment for TB and who underwent drug-resistance measurement and genotype of the isolated MTB bacilli before treatment started, and drug resistance and genotype in failure and/or recurrent TB cases
|
Inappropriate treatment regimens for diagnosed non-MDR-TB
|
Appropriate treatment regimens for non-MDR-TB
|
MDR-TB
|
